Recently, the China Primary Health Care Foundation launched the “Life-to-Kyrgyz-Lung Cancer Patient Assistance Programâ€, which was provided by Boehringer Ingelheim to the China Primary Health Care Foundation for free. Giotrif (common name: afatinib) The project aims to help patients with non-small cell lung cancer requiring TKI treatment to receive more durable and effective medical treatment.
It is understood that the type of assistance for the project includes two types, one is the subsistence allowance patients, that is, during the project implementation period, the urban subsistence allowance/rural deprivation non-small cell lung cancer patients who have been approved by the county/district civil affairs department for one year According to the evaluation of the doctors of the project hospital, it is suitable for the treatment of afatinib maleate tablets, and the free assistance of this project can be obtained until the disease progresses or the project is terminated. The other type is low-income patients, that is, the diagnosis is non-small cells. Lung cancer, and patients who have been treated with affitidine maleate for 7 months (30 boxes) are evaluated by the hospital doctors and need to be treated with afatinib maleate for further treatment. It is free of charge for the drugs needed for follow-up treatment until the disease progresses or the project is terminated.
During the progress of the project, the project team will conduct regular random checks on patients who have received aid drugs, check personal information and medical records, and stop assistance if they refuse to accept the test or if any medical conditions or economic conditions are found to be inconsistent.
On February 27, 2017, Boehringer Ingelheim announced that the only commercially available irreversible targeted drug, Gitari, has been approved by the CFDA for the treatment of advanced non-small cell lung cancer, and has been used for previously unrecognized EGFR. (EGFR) tyrosine kinase inhibitor (TKI) treatment, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR gene-sensitive mutations; locally advanced or metastatic scales of disease progression during or after platinum-containing chemotherapy Histological NSCLC patients.
Afatinib is a new generation of oral small molecule tyrosine kinase inhibitor (TKI), the first irreversible ErbB family blocker that acts on the entire ErbB family, including EGFR. Unlike the first-generation reversible EGFR TKI, afatinib binds irreversibly to EGFR, thereby shutting down the cancer cell signaling pathway and inhibiting tumor growth.
Clinical research data has confirmed the efficacy and safety of afatinib. The global series of clinical trials of afatinib has recruited more than 3,700 patients. It is the largest global series of clinical trials in the field of lung cancer to date, including 700. Several patients were from China and the project included a clinical study designed specifically for Chinese patients.
Clinical studies have shown that afatinib is the only TKI that prolongs the overall survival of patients with 19 exon deletions (the most common type of EGFR mutation) compared to the best chemotherapy regimen, with the first generation of EGFR TKI gefitinib In comparison, afatinib reduced the risk of lung cancer progression and the risk of treatment failure by 26%, and the number of progression-free patients who received afatinib after two years of treatment was twice that of gefitinib.
A head-to-head study in patients with lung squamous cell carcinoma after tumor progression or first-line chemotherapy showed that afatinib reduced cancer risk and risk of death by 19% compared with the first-generation EGFR TKI erlotinib. And can significantly improve disease control rates, improve quality of life and control of cancer symptoms.
Currently, afatinib has been approved in more than 70 countries for the treatment of patients with EGFR mutation-positive non-small cell lung cancer, and has become the first choice for EGFR-targeted drugs in several countries.
Pain Relief Patch(Pain Areas)
Pain Relief Patch
[Name] Medical Cold Patch
[Package Dimension] 6cm×8cm 4pieces/box
The pain relief patch is composed of three layers, namely, backing lining, middle gel and protective film. It is free from pharmacological, immunological or metabolic ingredients.
[Scope of Application]
For cold physiotherapy, closed soft tissue only.
[Indications]
The patches give fast acting pain relief for strains, sprains, cramp, bruises, swollen areas or joint stiffness.
[How To Use a Patch]
Please follow the Schematic Diagram. One piece, one time.
The curing effect of each piece can last for 6-8 hours.
[Attention]
Do not apply the patch on the problematic skin, such as wounds, eczema, dermatitis,or in the eyes. People allergic to herbs and the pregnant are advised not to use the medication. If swelling or irritation occurs, please stop using and if any of these effects persist or worsen.notify your doctor or pharmacist promptly. Children using the patch must be supervised by adults.
[Storage Conditions]
Store below 30c in a dry place away from heat and direct sunlight.
Pain Relief Patch(Pain Areas),Shouler Pain Relief Patch,Joints Pain Relief Patch, Muscle Pain Relief Patch
Shandong XiJieYiTong International Trade Co.,Ltd. , https://www.xijieyitongpatches.com